• AIM ImmunoTech’s Ampligen Featured in Peer-Reviewed Journal Cancers as a Potential Therapy... 6/15/2021
• AIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clini... 3/9/2021
• AIM ImmunoTech Inc.’s Drug Ampligen Awarded FDA’s Orphan Drug Designation Status for the T... 12/22/2020
• AIM ImmunoTech Files Patent Applications Surrounding Ampligen(R) Against Wuhan Novel Coron... 2/12/2020